KPV
Tripeptide fragment (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Retains the anti-inflammatory properties of alpha-MSH without melanocortin receptor activation. Inhibits NF-kB pathway and reduces pro-inflammatory cytokine production. Crosses mucosal barriers with demonstrated efficacy in colitis models.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- hs-crp
- wbc
- pregnancy
- PMID:15249167Systemic administration of alpha-MSH analogs inhibits gastrointestinal inflammation — Neuropeptides, 2004
- PMID:25398442Anti-inflammatory effects of alpha-MSH peptide fragments in intestinal epithelial cells — Peptides, 2015
KPV is the stripped-down anti-inflammatory fragment. Three amino acids from alpha-MSH that retain the NF-kB suppression without the melanocortin receptor effects. No tanning. No sexual side effects. Just the inflammatory shutdown. The oral route for gut-specific inflammation is the most logical application — a tripeptide that crosses the mucosal barrier to suppress inflammation locally. The colitis model data is encouraging. The human clinical data is absent. This is a T3 compound that may eventually move to T2 as the IBD research catches up.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See KPV in a protocol matched to you